Evaluation and Management of Suspected Peanut Allergy with Negative IgE Testing
When peanut-specific IgE testing is negative but clinical history suggests immediate peanut allergy, proceed with skin prick testing (SPT) as the next diagnostic step, and if SPT is also negative but history remains convincing, perform a supervised oral food challenge (OFC) to definitively establish or exclude the diagnosis.
Diagnostic Algorithm for Negative IgE Testing
The NIAID guidelines establish that a subset of patients with undetectable serum food-specific IgE antibody and negative SPT has been reported to have objective reactions confirmed by OFC 1. This critical finding means negative blood work does not rule out peanut allergy when clinical history is compelling.
Step-by-Step Approach:
1. Perform Skin Prick Testing (SPT)
- SPT can detect peanut allergy even when serum IgE is negative
- A wheal ≥3 mm is considered positive and supports the diagnosis 1
- Negative SPT combined with negative IgE makes true allergy less likely but does not exclude it
2. Consider Component-Resolved Diagnostics (CRD)
- Test for Ara h 2-specific IgE, which is the most specific marker for peanut allergy (specificity 0.92, PPV 0.94) 2
- Ara h 2 provides better diagnostic accuracy than whole peanut IgE (AUC 0.84) 2
- Recent data shows Ara h 2 can identify peanut allergy with 96.6% PPV even when whole peanut IgE is low 3
- This two-step approach (SPT followed by Ara h 2) reduces unnecessary OFCs by 27.8% 4
3. Proceed to Oral Food Challenge if Testing Remains Inconclusive
- OFC is the gold standard when history and testing are discordant 1
- Must be performed in a supervised medical setting with emergency equipment available
- Risk stratification before OFC is essential (see below)
Risk Assessment Before OFC
High-Risk Features (Defer or Hospital-Based OFC):
- Recent reaction (past 6-12 months) to peanut
- History of severe reaction (respiratory symptoms, cardiovascular involvement, or ≥4 organ systems)
- Presence of asthma (regardless of severity)
- Reaction to trace amounts of peanut
- Conditions affecting resuscitation (cardiovascular disease, difficult vascular access) 1
Lower-Risk Features (Office-Based OFC Acceptable):
- Recent accidental ingestion of small amounts without symptoms
- No past severe reactions
- No asthma
- Longer time since last reaction 1
Emergency Preparedness
All patients with suspected peanut allergy should be prescribed epinephrine auto-injectors pending definitive diagnosis, as the NIAID guidelines emphasize that peanut is frequently implicated in fatal and near-fatal anaphylaxis [@1-4@].
Epinephrine Dosing:
- 10-25 kg: 0.15 mg IM (anterior-lateral thigh)
- >25 kg: 0.3 mg IM (anterior-lateral thigh)
- May repeat every 5-15 minutes as needed [@1-4@]
Critical Pitfalls to Avoid
Do not dismiss a convincing clinical history based solely on negative IgE testing. The Johns Hopkins study documented that 33% of patients were identified based on positive SPT or peanut sIgE without any history of peanut exposure, highlighting that testing can be falsely positive—but the converse is also true: testing can be falsely negative 5.
Do not perform OFC in an unmonitored setting. Even with negative testing, OFC carries risk of anaphylaxis (1.1% in recent cohorts) 4.
Do not delay evaluation in young children. Early intervention (ages 1-3 years) shows superior outcomes, and the natural history of untreated peanut allergy involves increasing IgE levels and clinical reactivity over time 6.
When to Refer to Allergist
Refer immediately if:
- Discordance between negative testing and convincing history of immediate reaction
- Need for supervised OFC
- History of severe reaction requiring risk stratification
- Patient requires clearance for high-stakes situations (military service, occupational requirements) 7
The integration of clinical history with sequential testing (whole peanut IgE → SPT → Ara h 2 → OFC) provides the most accurate diagnostic pathway while minimizing unnecessary challenges and maintaining patient safety 4, 2.